# HMG: Clinical Guide for Practices

> HMG (Human Menopausal Gonadotropin) is a gonadotropin preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is used in fertility medicine for ovulation induction and increasingly in men's health as an alternative or adjunct to HCG for spermatogenesis stimulation during testosterone replacement therapy.

**FDA compounding category:** Compounding eligibility varies; verify current FDA status before prescribing  
**Category:** Hormonal Support  
**Route of administration:** Intramuscular injection, subcutaneous injection

## Mechanism of action

HMG provides exogenous FSH and LH activity derived from purified urinary gonadotropins [2]. The FSH component directly stimulates Sertoli cells to support spermatogenesis, while the LH component stimulates Leydig cells for testosterone production [3]. This dual-axis stimulation distinguishes HMG from HCG, which provides only LH-like activity [1].

## Evidence summary

Clinical studies demonstrate that combined FSH/LH therapy (HMG) is more effective than LH stimulation alone for restoring spermatogenesis in hypogonadotropic hypogonadism [1]. A meta-analysis by Attia et al. (2007) confirmed superior sperm count outcomes with FSH-containing regimens [1]. A systematic review by Santi et al. further validated FSH efficacy in male infertility [3].

## Patient selection

Primary candidates include men with hypogonadotropic hypogonadism who have failed HCG monotherapy for spermatogenesis, and those with persistently low sperm counts despite adequate intratesticular testosterone [1]. Female candidates include anovulatory patients pursuing IVF or IUI [2]. Patients with primary testicular failure (elevated FSH) are unlikely to respond [3].

## Clinical uses

- Spermatogenesis stimulation in men on TRT or with hypogonadotropic hypogonadism
- Ovulation induction in assisted reproductive technology (ART)
- Male fertility preservation as alternative or adjunct to HCG
- Hypogonadotropic hypogonadism (both male and female)
- Controlled ovarian hyperstimulation for IVF protocols

## Protocols and dosing

Administered via intramuscular or subcutaneous injection. In male fertility protocols, typical dosing is 75-150 IU 2-3 times weekly, often combined with HCG. Dosing is titrated based on semen analysis and hormone levels.

In men with hypogonadotropic hypogonadism, begin with HCG 1500 IU twice weekly for 3-6 months; if semen analysis remains suboptimal, add HMG 75-150 IU three times weekly [1]. Titrate HMG dose upward at 3-month intervals based on sperm count response [3]. In female IVF protocols, dosing is individualized by the reproductive endocrinologist based on follicular response and estradiol levels [2].

## Side effects to monitor

- Injection site pain and local reactions
- Ovarian hyperstimulation syndrome (OHSS) in female patients
- Gynecomastia and estradiol elevation in male patients
- Headache and fatigue
- Multiple gestation risk in female fertility protocols

## Clinical considerations

Contains both FSH and LH activity, providing dual gonadotropin stimulation,More complex dosing and monitoring requirements than HCG alone,Monitor estradiol, testosterone, FSH, LH, and semen analysis regularly,Risk of ovarian hyperstimulation syndrome (OHSS) in female patients,Compounding availability may be limited; verify with pharmacy partner

## Practice economics

HMG occupies a specialized niche in fertility-focused men's health protocols [1]. While per-unit cost is higher than HCG, it is essential for the subset of TRT patients where HCG alone fails to restore spermatogenesis [3]. Offering HMG positions a practice as a full-service fertility preservation clinic rather than a basic TRT provider, supporting premium pricing and referral relationships with reproductive endocrinologists.

## Frequently asked questions

### How does HMG differ from HCG in male fertility protocols?

HCG mimics LH only, stimulating Leydig cells to produce testosterone. HMG provides both FSH and LH activity, directly stimulating Sertoli cells (via FSH) for spermatogenesis in addition to Leydig cell stimulation. HMG is often preferred when semen analysis shows inadequate response to HCG alone, or in hypogonadotropic hypogonadism where both gonadotropins are deficient.

### When should a clinician add HMG to a TRT protocol instead of using HCG alone?

Consider adding HMG when patients on HCG monotherapy show persistent oligospermia or azoospermia, when FSH levels are low (indicating insufficient Sertoli cell stimulation), or when fertility is a primary treatment goal and HCG alone has not restored adequate sperm counts after 3-6 months. The FSH component of HMG directly drives spermatogenesis.

### What monitoring is required for men on HMG therapy?

Monitor semen analysis (every 3 months minimum), total and free testosterone, estradiol, FSH, LH, and hematocrit. Initial semen analysis improvement may take 3-6 months given the spermatogenic cycle length. Adjust dosing based on sperm count response and hormonal markers. Estradiol monitoring is important as gonadotropin stimulation can increase aromatization.

## Sources

- [Attia et al. - Meta-analysis of gonadotropin therapy for male infertility (2007)](https://pubmed.ncbi.nlm.nih.gov/17482179/)
- [Menopur (menotropins) FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021322s007lbl.pdf)
- [Santi et al. - Efficacy of FSH in male infertility: a systematic review (2015)](https://pubmed.ncbi.nlm.nih.gov/25800848/)

---

Canonical page: https://karpahealth.com/resources/peptides/hmg/
Markdown version of the HTML page "hmg" at that URL.
Machine-readable context: https://karpahealth.com/llms.txt · Pricing: https://karpahealth.com/pricing.md · Agents & API: https://karpahealth.com/agents.md